Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2011, Article ID 345012, 4 pages
http://dx.doi.org/10.1155/2011/345012
Clinical Study

Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients

1Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Primary Children's Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84113-1103, USA
2Pharmacy Department, Primary Children's Medical Center, Salt Lake City, UT 84113-1100, USA
3Department of Pediatrics, Primary Children's Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84113-1100, USA
4Pharmacy Department, MaKay-Dee Hospital Center, Intermountain Healthcare, Ogden, UT 84403, USA
5Department of Pediatric Pulmonology, Primary Children's Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84158, USA

Received 9 August 2011; Revised 19 September 2011; Accepted 20 September 2011

Academic Editor: P. Gionchetti

Copyright © 2011 John F. Pohl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. J. Novak, “Cystic fibrosis,” in Pharmacotherapy Principles and Practice, M. A. Chisholm-Burns, B. G. Wells, and T. L. Schwinghammer, Eds., McCraw-Hill, New York, NY, USA, 2008. View at Google Scholar
  2. H. Hendriks, B. Kreel, and P. Forget, “Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients,” Journal of Pediatric Gastroenterology and Nutrition, vol. 33, no. 3, pp. 260–265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Proesmans and B. K. Omeprazole, “Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes,” European Journal of Pediatrics, vol. 162, no. 11, pp. 760–763, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. F. Pohl, “Nutrition in cystic fibrosis,” Practical Gastroenterology, vol. 34, no. 3, pp. 20–27, 2010. View at Google Scholar · View at Scopus
  5. T. Tran, A. van den Neucker, J. Hendriks, P. Forget, and P. P. Forget, “Effects of a proton-pump inhibitor in cystic fibrosis,” Acta Paediatrica, vol. 87, no. 5, pp. 553–558, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Sayedy, D. Kothari, and R. Richards, “Toxic megacolon assoiciated Clostridium difficile colitis,” World Journal of Gastrointestinal Endoscopy, vol. 2, pp. 293–297, 2010. View at Google Scholar
  7. S. Dial, J. Delaney, A. Barkun, and S. Suissa, “Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease,” Journal of the American Medical Association, vol. 294, no. 23, pp. 2989–2995, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. Leonard, J. K. Marshall, and P. Moayyedi, “Systematic review of the risk of enteric infection in patients taking acid suppression,” American Journal of Gastroenterology, vol. 102, no. 9, pp. 2047–2056, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. S. Dial, K. Allrasadi, C. Manoukian et al., “Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies,” Canadian Medical Association Journal, vol. 17, no. 1, pp. 33–38, 2004. View at Google Scholar
  10. K. Yearsley, L. Gilby, A. Ramadas, E. M. Kubiak, D. L. Fone, and M. C. Allison, “Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 4, pp. 613–619, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. Cadle, M. Mansouri, L. Logan, D. R. Kudva, and D. M. Musher, “Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis,” American Journal of Health-System Pharmacy, vol. 64, no. 22, pp. 2359–2363, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. Jayatilaka, R. Shakov, R. Eddi, G. Bakaj, W. J. Baddoura, and V. A. DeBari, “Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors,” Annals of Clinical and Laboratory Science, vol. 37, no. 3, pp. 241–247, 2007. View at Google Scholar · View at Scopus
  13. K. J. Preacher, “Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software],” http://quantpsy.org/.
  14. A. Elixhauser and M. Jhung, Clostridium difficile-associated disease in U.S. hospitals, 1993–2005: Statistical brief #50. Healthcare Cost and Utilization Project Statistical Briefs [Internet]. Agency for Health Care Policy and Research (US): 2006–2008.
  15. N. Werner, M. Hecker, A. Sethi, and C. J. Donskey, “Unnecessary use of fluoroquinolone antibiotics in hospitalized patients,” BMC Infectious Diseases, vol. 11, article 187, 2011. View at Publisher · View at Google Scholar · View at PubMed
  16. C. Pokorny, B. Bye, C. Macleod, and W. S. Selby, “Antibiotic-associated colitis and cystic fibrosis,” Digestive Diseases and Sciences, vol. 37, no. 9, pp. 1464–1468, 1992. View at Google Scholar · View at Scopus
  17. S. L. Peach, S. P. Borriello, and H. Gaya, “Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis,” Journal of Clinical Pathology, vol. 39, no. 9, pp. 1013–1018, 1986. View at Google Scholar · View at Scopus
  18. C. P. Kelly, C. Pothoulakis, and J. T. LaMont, “Clostridium difficile colitis,” New England Journal of Medicine, vol. 330, no. 4, pp. 257–262, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Chaun, “Colonic disorders in adult cystic fibrosis,” Canadian Journal of Gastroenterology, vol. 15, no. 9, pp. 586–590, 2001. View at Google Scholar · View at Scopus
  20. J. Rivlin, A. Lerner, A. Augarten, M. Wilschanski, E. Kerem, and M. A. Ephros, “Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis,” Journal of Pediatrics, vol. 132, no. 1, pp. 177–179, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Kim, K. Lee, J. Jeong et al., “Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea,” World Journal of Gastroenterology, vol. 16, no. 28, pp. 3573–3577, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Howell, V. Novack, P. Grgurich et al., “Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection,” Archives of Internal Medicine, vol. 170, no. 9, pp. 784–790, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. S. Naggie, B. Miller, K. Zuzak et al., “A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors,” American Journal of Medicine, vol. 124, no. 3, pp. 276-e1–276-e7, 2011. View at Publisher · View at Google Scholar · View at PubMed
  24. A. Lisowska, E. Mdry, A. Pogorzelski, J. Szydłowski, A. Radzikowski, and J. Walkowiak, “Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 5, pp. 322–326, 2010. View at Publisher · View at Google Scholar · View at PubMed
  25. M. Segarra-Newnham, “Probiotics for Clostridium difficile associated diarrhea: focus on Lactobacillus rhanosus GG and Saccharomyces boulardii,” Annals of Pharmacotherapy, vol. 41, no. 7-8, pp. 1212–1221, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus